Investment Rating - The report indicates a positive outlook for the pharmaceutical sector, particularly for innovative drugs and companies expected to reach profitability in 2025 [1][9][15]. Core Insights - The innovative drug sector is anticipated to see significant growth due to the commercialization of core products and contributions from business development (BD) revenues, with companies like BeiGene, Innovent Biologics, and others expected to achieve profitability [1][9]. - The Pharma sub-sector is projected to experience a revenue growth rate of 15-20% in 2025, with notable companies such as Hansoh Pharmaceutical and China Biologic Products leading this growth [2][10]. - The CXO sector is also expected to report strong performance, with companies like WuXi AppTec forecasting substantial revenue and profit increases [3][11]. - The medical services sector is currently valued at historical lows, with a projected revenue growth of 13% for Genscript Biotech, highlighting the importance of monitoring industry changes [4][12]. Summary by Sections Innovative Drugs - Companies expected to achieve profitability in 2025 include BeiGene, Innovent Biologics, and others, driven by increased commercialization and BD revenues [1][9]. Pharma - Revenue growth of 15-20% is expected for leading companies such as Hansoh Pharmaceutical and China Biologic Products, with a significant boost anticipated for 3SBio due to a major BD deal with Pfizer [2][10]. CXO - WuXi AppTec is projected to achieve approximately 454.56 billion RMB in revenue, reflecting a year-on-year growth of about 15.84%, with adjusted net profits expected to rise significantly [3][11]. Medical Services - Genscript Biotech is expected to see a revenue increase of 13% in 2025, emphasizing the need to focus on overseas business expansion and AI integration in traditional medicine [4][12].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HK$10.59, representing a potential upside of 20% from the current price of HK$8.84 [1][8][18]. Core Insights - The company has faced revenue declines in its core pharmaceutical business but has offset some of this through strong licensing income, demonstrating its ability to commercialize its pipeline effectively [6][15]. - The report highlights a strategic partnership with AstraZeneca, which includes an upfront payment of US$110 million, indicating strong collaboration in innovative drug development [6][15]. - Adjustments to earnings per share (EPS) forecasts reflect a cautious outlook on the growth of the company's core generic drug business, with 2025 and 2026 EPS estimates reduced by 14% [2][11]. Financial Performance - The company reported a revenue of RMB 70.15 billion in Q1 2025, a year-on-year decline of 21.9%, while net profit was RMB 14.95 billion, down 8.3% [6][10]. - The revenue forecast for 2025 has been adjusted down to RMB 28.306 billion, a decrease of 12% from previous estimates, with a further decline expected in 2026 [12][15]. - The report anticipates a gross margin of 70% for 2025, slightly lower than previous forecasts, reflecting ongoing challenges in the market [11][12]. Research and Development - The company continues to invest in R&D, with expenditures reaching RMB 13 billion in Q1 2025, representing an 11.4% increase year-on-year [7][11]. - The R&D intensity remains high at 23.7% of revenue, indicating a strong commitment to innovation [7][11]. - The company has nearly 90 products in various stages of clinical development, with several already submitted for registration, enhancing future approval efficiency [7][11]. Valuation - The report employs a two-stage DCF model for valuation, adjusting the WACC to 8.5% and increasing the perpetual growth rate to 4% [8][17]. - The target price of HK$10.59 is based on the DCF analysis, suggesting that the current valuation does not fully reflect the company's growth potential in innovative drugs and licensing income [8][17]. - The company's projected P/E ratio for 2025 is 21, slightly above the industry average of 20, indicating a potential undervaluation relative to its peers [8][17].